Helsby NA[au] - Search Results

Year	Number of Results
1990	2
1991	2
1993	1
1995	1
1997	1
1998	2
1999	1
2000	1
2002	1
2003	1
2004	2
2005	2
2006	1
2007	3
2008	4
2009	2
2010	5
2011	4
2012	3
2013	1
2014	3
2015	3
2016	2
2017	1
2018	2
2019	5
2020	1
2021	5
2022	1
2023	0

1

CYP2C19 and CYP2D6 genotypes in Pacific peoples.

Helsby NA. Helsby NA. Br J Clin Pharmacol. 2016 Nov;82(5):1303-1307. doi: 10.1111/bcp.13045. Epub 2016 Aug 26. Br J Clin Pharmacol. 2016. PMID: 27304207 Free PMC article. Review.

2

Pharmacogenetics of drug-metabolizing enzymes: the prodrug hypothesis.

Begg EJ, Helsby NA, Jensen BP. Begg EJ, et al. Among authors: helsby na. Pharmacogenomics. 2012 Jan;13(1):83-9. doi: 10.2217/pgs.11.134. Pharmacogenomics. 2012. PMID: 22176624 Review.

3

THE CONCISE GUIDE TO PHARMACOLOGY 2021/22: Enzymes.

Alexander SP, Fabbro D, Kelly E, Mathie A, Peters JA, Veale EL, Armstrong JF, Faccenda E, Harding SD, Pawson AJ, Southan C, Davies JA, Boison D, Burns KE, Dessauer C, Gertsch J, Helsby NA, Izzo AA, Koesling D, Ostrom R, Pyne NJ, Pyne S, Russwurm M, Seifert R, Stasch JP, van der Stelt M, van der Vliet A, Watts V, Wong SS. Alexander SP, et al. Among authors: helsby na. Br J Pharmacol. 2021 Oct;178 Suppl 1:S313-S411. doi: 10.1111/bph.15542. Br J Pharmacol. 2021. PMID: 34529828 Free article.

4

The importance of both CYP2C19 and CYP2B6 germline variations in cyclophosphamide pharmacokinetics and clinical outcomes.

Helsby NA, Yong M, van Kan M, de Zoysa JR, Burns KE. Helsby NA, et al. Br J Clin Pharmacol. 2019 Sep;85(9):1925-1934. doi: 10.1111/bcp.14031. Epub 2019 Jul 22. Br J Clin Pharmacol. 2019. PMID: 31218720 Free PMC article. Review.

5

Using metabolomic analysis to understand inflammatory bowel diseases.

Lin HM, Helsby NA, Rowan DD, Ferguson LR. Lin HM, et al. Among authors: helsby na. Inflamm Bowel Dis. 2011 Apr;17(4):1021-9. doi: 10.1002/ibd.21426. Inflamm Bowel Dis. 2011. PMID: 20629098 Review.

6

Ethnic disparity in clozapine dosing and cardiotoxicity in New Zealand.

Burns KE, Bellissima BL, Garavan F, Helsby NA, Tingle MD. Burns KE, et al. Among authors: helsby na. N Z Med J. 2022 May 20;135(1555):32-40. N Z Med J. 2022. PMID: 35728233

7

Pheno- or genotype for the CYP2C19 drug metabolism polymorphism: the influence of disease.

Helsby NA. Helsby NA. Proc West Pharmacol Soc. 2008;51:5-10. Proc West Pharmacol Soc. 2008. PMID: 19544664 Review.

8

Pharmacogenomics in Papua New Guineans: unique profiles and implications for enhancing drug efficacy while improving drug safety.

Tucci JD, Pumuye PP, Helsby NA, Barratt DT, Pokeya PP, Hombhanje F, Somogyi AA. Tucci JD, et al. Among authors: helsby na. Pharmacogenet Genomics. 2018 Jun;28(6):153-164. doi: 10.1097/FPC.0000000000000335. Pharmacogenet Genomics. 2018. PMID: 29768302 Review.

9

Intracellular activation of 4-hydroxycyclophosphamide into a DNA-alkylating agent in human leucocytes.

Yong M, Burns KE, de Zoysa J, Helsby NA. Yong M, et al. Among authors: helsby na. Xenobiotica. 2021 Oct;51(10):1188-1198. doi: 10.1080/00498254.2021.1975060. Epub 2021 Sep 8. Xenobiotica. 2021. PMID: 34470569

10

Validating TDP1 as an Inhibition Target for the Development of Chemosensitizers for Camptothecin-Based Chemotherapy Drugs.

Leung E, Patel J, Hollywood JA, Zafar A, Tomek P, Barker D, Pilkington LI, van Rensburg M, Langley RJ, Helsby NA, Squire CJ, Baguley BC, Denny WA, Reynisson J, Leung IKH. Leung E, et al. Among authors: helsby na. Oncol Ther. 2021 Dec;9(2):541-556. doi: 10.1007/s40487-021-00158-0. Epub 2021 Jun 23. Oncol Ther. 2021. PMID: 34159519 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results